Fluorinated Ultralong-Acting Neuromuscular Blocking Agent with Improved Activity Profile and Biosafety for the Development of Blockade and Reversal Partner Drugs
. The two agents thus form a promising partnership featuring ultralong-acting blockade and on-demand reversal.
Authors
- D Y Zhang
- Zhan‐Ting Li (ORCID: https://orcid.org/0000-0003-3954-0015)
- Shang‐Bo Yu (ORCID: https://orcid.org/0000-0001-7186-367X)
- Ru-Lei Zhang (ORCID: https://orcid.org/0009-0007-3026-4452)
- Gang Zhao (ORCID: https://orcid.org/0000-0002-0162-7783)
- Shi-Xian Gan
- W Y Zhou
- Qiao-Yan Qi (ORCID: https://orcid.org/0009-0002-7902-9676)
- Ke Feng (ORCID: https://orcid.org/0000-0003-2024-6393)
- Hui Wang (ORCID: https://orcid.org/0000-0002-0704-823X)
- Congying Guo (ORCID: https://orcid.org/0009-0005-0913-9919)
Institutions
- Harbin Institute of Technology (CN)
- Fudan University (CN)
- Ascepion Pharmaceuticals (China) (CN)
- Shanghai Institute of Organic Chemistry (CN)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-05-29
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c01353
- Primary Topic
- Pharmacological Effects and Assays
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China